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Abstract
Purpose The purpose of the study was to determine the sites
and types of mutations associated with type I neurofibroma-
tosis (NF1) in the NF1 gene in a family with NF1 patients.
Methods The blood samples obtained from this family (four
patients and one normal healthy individual) were analyzed
by performing polymerase chain reaction (PCR) and DNA
sequencing for mutation screening.
Results We found synonymous mutations in exons 7, 38,
50, and 56 of the NF1 gene. This implied that the third
codon had a new SNP that did not lead to a change in the
amino acid coding. The exon 19 mutation was CAG homo-
zygous, while it was C/TAG heterozygous in normal indi-
viduals. The stop codon led to nonsense-codon-mediated
decay of the mRNA (NMD), thus resulting in only one copy
of the NF1 gene that encodes the normal protein in
individuals.
Conclusions The synonymous mutations in the NF1 gene
occur in exons 7, 38, 50, and 56. The CAG homozygous
mutations may occur in exon 19, and the C/TAG heterozy-
gous mutations may occur in the others. This mutation may
be responsible for NF1 in patients in this family and may
warrant extensive research on the NF1 gene.
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Introduction
Neurofibromatosis (NF) is a common dominant genetic
disease that is caused by an aberration in a dominant gene
and manifests as tumors of neuroectodermal and mesoder-
mal origin. It is characterized by multi-system and multi-
organ involvement, especially involvement of the central
nervous system, and a variety of tumors. Type I NF, also
known as the Von Recklinghausen disease, is the most
common type. The gene located on chromosome 17q11.2
is the main cause of multiple nervous system tumors char-
acterized by pigmented skin lesions and multiple NF; it may
also be associated with mental retardation, neurological
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NF1 is currently reported to be associated with a total of 728
mutations, including base substitutions, major mutations,
insertions, deletions, nonsense mutations, missense muta-
tions, and frameshift mutations. Most mutations can lead
to the production of truncated proteins. By using polymer-
ase chain reaction (PCR) and DNA sequencing, we screened
members of a Chinese family for NF gene mutations and
found that four members had NF1 and one was normal and
healthy.
Materials and methods
Clinical data
We collected the dossiers on a family with patients having
type I NF from the Shandong Cancer Hospital between 2009
and 2010. We had data on eight people in the family, of
whom six were diagnosed with type I NF. All the patients
were diagnosed on the basis of the US NIH diagnostic
standard of the year 1987.
The clinical data of three generations of the family has
been shown in Fig. 1. The proband (III1) was a 21-year-old
woman who had undergone a surgery at the age of 9 years
because of a swelling and pain in her left lower extremity
along with coffee-with-milk spots (Fig. 2); the pathological
diagnosis was NF (Fig. 3). Case I 1 was of a 69-year-old
man who had lesions on his abdominal wall, arms, angle of
the eyes, and other sites (Fig. 4), and case I 2 was of a
healthy female family member. Case II 1 was of a 36-year-
old woman with a 1-year history of NF, and case II 2 was of
a 40-year-old man with dorsal neurofibroma (Fig. 5). Case II
1 was of a 40-year-old woman who was a healthy subject,
and case II 2 was of a 7-year-old girl showing coffee-with-
milkspots;she did not haveNF. Case III 3 wasofa 1-year-old
female child with coffee-with-milk spots and no NF.
DNA extraction
Our study was approved by the medical ethics committee of
the hospital, and we obtained informed consents from the
family members before collecting peripheral blood samples
from four patients diagnosed with NF (I 1, II 1, II 2, III 1)
and one normal healthy subject (II 3) of the same family. We
stored the blood samples at −85°C in an ultra-low temper-
ature freezer. We extracted the NF1 gene DNA by using a
modified salting-out and precipitation techniques and mea-
sured the DNA concentration by using a spectrophotometer.
Primer design
We used the NCBI database to obtain the NF1 salting-out
and precipitation techniques salting-out and precipitation
techniques gene sequence salting-out and precipitation tech-
niques and the Primer 5.0 software for designing the primers
required to amplify the region coding for the NF1 gene
(Table 1).
Fig. 1 A diagram showing the affected members of the family
Fig. 2 Patient III 1. A diagram showing the affected members of the
family axillary coffee-with-milk spots
Fig. 3 Patient III 1. Postoperative pathological examination
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The PCR reaction setup has been shown in Table 2. This
reaction was set up in the Biometra PCR instrument, and the
reaction conditions were as follows: polymerization at 95°C
for 5 min, followed by cooling in an ice bath, a quick spin,
addition of 1 μl Taq DNA polymerase, and a final quick spin
for mixing. The thermal cycling amplification conditions
were as follows: pre-denaturation reaction at 96°C for
3 min, denaturation at 96°C for 30 s, annealing at 55°C
for 55 s, extension at 72°C for 30 s, and lastly a final
extension at 72°C for 10 min. The PCR amplification prod-
ucts were analyzed by performing agarose gel electrophore-
sis. We used Exon I and the shrimp alkaline phosphatase
enzyme for purification.
DNA sequencing
DNA was sequenced by DNA dideoxy sequencing method
by using Biomek FX Beckman fluid moving workstation
and a NanoDrop 8000 spectrophotometer. We then trans-
ferred the reaction plate to the Applied Biosystems 3730 XL
fully automatic DNA sequencing instrument and electro-
phoresed the samples. When we obtained abnormal DNA
sequencing results, we used the TA cloning system kit
(Invitrogen, San Diego, CA) and directly sequenced the
PCR products; we then constructed a color map representing
the DNA sequence.
Results
We detected NF1 gene mutations in five blood samples from
this family by direct sequencing and DNA cloning methods,
and we found totally synonymous mutations in four NF1
exons—exon 7, exon 38, exon 50, and exon 56. These
mutations were new single-nucleotide polymorphisms
(SNPs), located on the third codon position, and the amino
acid coding did not change. We used a combination of
specific primers and universal primers for sequencing, but
the peaks were disordered, which indicated that this part of
the exon possibly had an indel mutation and should be
sequenced. On comparison of the forward and reverse se-
quencing results, we observed that this part of the exon had
a more complex structure and had both an SNP and a
deletion mutation, which should be sequenced.
Cloning and sequencing of exons 18, 19, 20, 22, 23, 26,
27, and 36 showed that these exons were completely normal
and that there was a nonsense mutation in exon 19 (CAG
[glutamine]>TAG [stop codon]) (see Fig. 6). The normal
healthy individual was a CAG homozygote, and the patients
were C/TAG heterozygotes. The stop codon led to
nonsense-codon-mediated mRNA decay (NMD), which
led to the formation of only one copy of the NF1 gene that
encodes the normal protein in individuals.
Discussion
NF is a common autosomal dominant genetic disease man-
ifested as neuroectodermal abnormalities. There are approx-
imately 15 million NF patients worldwide with a clear
family history, often involving multiple systems and organs
[3]. In Von Recklinghausen disease (or NF1-type), the ab-
errant gene is located on human chromosome 17q11.2 and
has a length of 350 kb, with 60 exons; the transcription
length is about 11–13 kb, also a 315-kb region of chromo-
some that is composed of three untranslated regions. Kang
et al. [4] found that specific methylation can occur at the
transcription-factor-specific binding sites on the NF1 gene
promoter, which is parallel and conformal to tumor cell
genome hypomethylation.
NF1 gene mutations mainly include DNA replication
errors, point mutation, and other mutations, with replication
errors accounting for 20% to 30% gene mutations. The
Fig. 4 Patient I 1. Neurofibroma on the anterior chest
Fig. 5 Patient III 2. Dorsal neurofibroma surgery
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the target gene Exons Primer sequence (5′→3′) PCR product length (bp)
E1 GAGCCTGCACTCCACAGACCC 297
TCCTCCAGAGCCTGAGGCAGC
E 2 ATGGCAAGTAAGTTATTTATGGTC 331
TATCCAAAGTCCACAGAAAATCA
E 3 GAGGTAAAATGGAAGACTATTGTTG 363
AAAATTGTCTGTCACCAGGTCAG
E 4 TGGTAAGGATGGCAGGGGGATTG 465
TCCCATGTGGATTTACACACTAACC
E5 GATGTCTTGCTATGTTGCCCAGG 479
ATTGCCAAGATTTAAAATGCTCA
E6–7 AATCATTGATGTCCAAGGCATAT 723
TTTCCTATTTGACACCAGTTGAC
E8 CCAGGGATTTTGTTCCTATCTAA 483
CAGAGGTATCGTTTAGTCTTCTCAGA
E9 TTCTTTATAGTATGAGTTTTAGAGGC 402
GAACTTATCAACGAAGAGTCAGA
E10–11 GGGTGCTTTGTGCTTCTTCTGGC 651
AAGAAATACGCAAAGAAAAGAAAGA
E12 TGGAAATCATGGTGTGTGTTTGC 361
AAAATAACCAAAGCAGCAGGAAT
E13 AATACTGACCTTATGCTTACTATTGA 384
TATCCTCAAGGTCTTGGCGTTTC
E14 TTGAAGTTTCCTTTTTTTCCTTGCA 221
AAACCACACACCAAAGGAACATCAT
E15 AATGAAAGAGCTCAATTTCTTAGCA 315
AAACCATAAAACCTTTGGAAGTGTA
E16 CTCTAAACTTGTATTCATTATGGGAGA 288
ATCTCTCACCATTACCATTCCAA
E17 ATTCCTCTTGGTTGTCAGTGCTT 260
AACAAACAGAGCACATAAAATGATACA
E18 TTATACATAAAATTACCCAAGTTGCA 337
ACTGAGTAAAAAAAACCACTATTCACA
E19–20 TGGCAGGCAGGGCTCTAAGTG 473
TAACAGACAAAAGTCAACTTTACAGA
E21 TAAGGTTTAATTCATGCTTTGCA 516
ATAGAGAAAGGTGAAAAATAAGAGAAC
E22–23 CTCTAGGGGGTCTGTCTTCTGGG 518
TGGACCATATTCCCAAGCACACG
E24 TGTCACTTAGGTTATCTGGCAAA 453
CTGTAGACTATTCTTCATAAACTGACAAC
E25 TTTAAGGTAGCCATTTTGCCAAGAT 400
TTGCTTTATGTTTTTTGGTGACT
E26–27 TTGTTTTGGAATGTCTGGTTAGC 622
ACTTTTCTTCCCCGCTTACTCTA
E28–29 TTCCTACCTAAGAATAAAAATGGGA 502
AACAGCGGTTCTATGTGAAAAGAT
E30 CGTAAGCCATCCAGCCCTGTCAA 460
CAATTCTCAATGTATTATTCATCCAAAC
E31 TGTTGCTGTATGTAGTCGGTGCT 226
724 Childs Nerv Syst (2012) 28:721–727Table 1 (continued)
Exons Primer sequence (5′→3′) PCR product length (bp)
TTTACAGTGAAGGTCAAATAGGC
E32 GGACTGATTGATTCAGAGTTTTTATG 389
GCACATAACTGAAAACCATAGGG
E33 TATTTGGGAAGGTTAGAAACACT 305
GAGCAACTGAGTAAGTGGCAAGA
E34 ATAAGTCTGGGTGTATCTGGTGT 459
AAAGAGCAAATCTGTGATTTCTT
E35 GGGAAAAGTAGTGGACTGTGAAGC 452
GTGGCAAACTCTCCTTCTCAACC
E36 TACCCTTTAGAATGCCTGTTGCT 318
AACTTGCCATCTCTCTATATTTGCTA
E37 ATTCCCACTGTTTTCTTCCTTTC 776
GAGGCCAGGATATAGTCTAGTTAGTCA
E38 ATTCTTCTCCACTTCACCCCGTC 417
ACCCCAAATCAAACTGAAGAGAA
E39 AAGGGGTATTTTGGTTTTACTGTAG 622
TAAAGTACCAAACTCTTGCCGCT
E40 CAGGCCTGATTCTAGGTAATAGTCTT 432
ACTGTGTTTTTTACAACTCTATCCCTA
E41–42 ATCTCTTAATCTCTGAAGGAGTCAA 865
TCAGGTGAAGTAAAATGGAGAAA
E43 AATACTCAGTGCCAGTTGACCAT 676
ATGCCTAAAAAAGGGGATACTCT
E44–45 CAATATGTATTCAGAGTATCCCCTTT 384
ATATTTGGGAGAAGTGAGGGCGG
E46 TCCGAGATTCAGTTTAGGAGTTA 342
CTAATATGACTACTTCAAACAACTAAA
E47 GAAGAATCAACAAACCTTGGTGA 480
GCAACAAGAAAAGATGGAAGAGTAC
E48 AAGAAAGCTACTGTGTGAACCTCAT 511
GCTCAAGCAATCCTTCCATCTAT
E49 GTCAGGGAAGAAGACCTCAGCAG 333
ACTGTGAACTTTCTGCTCTGCCA
E50 GTTTCTCTACTCAGCAACACTTAGC 754
AGCACAATCAGACTGGAAGAATAA
E51 ACTTGGAAGGAGCAAACGATGGT 496
AGCAAAGGCAAAACAAAATAAGG
E52 TTAAACACTTTATGTCCAAACATTT 437
TGGCTACCTATTTACAATGCTGT
E53–54 GGTGAAGTGATTATCCAGGTGTT 515
TTAACTTAAAGACAGGCACGAAG
E55–56 AATGAAGAAATGCCCCAGAAAG 769
CATTGTGTGTTCTTAAAGCAGGC
E57 TATTTTTGGCTTCAGATGGGGAT 439
AAAGTCAAGTCAGTTACAAGGTA
E58 AATGTGTCCCCGTTGTTAAGCGA 310
GGGCAAGGACAGGGAAGGGG
Childs Nerv Syst (2012) 28:721–727 725addition or deletion of a small direct repeat sequence in the
open reading frame can result in deletion of a terminal
inverted repeat sequence during replication, or when skipped
reading phenomenon in gene sequence occurs and DNA
hairpin-like structure is formed, which eventually leads to
the deletions of some DNA sequences. The mechanism un-
derlying these two mutations—in which a single-base substi-
tution results in a missense or a nonsense mutation known as
genepointmutation—isfairlycomplexandunclear.Thepoint
mutations are missense mutations with an incidence of about
5–10%, and nonsense mutations have an incidence of approx-
imately 30–38%. The incidence of missense mutations or
nonsense mutations that may affect RNA splicing is 20% to
35%.Ourstudyshowedthatsynonymousmutationscanoccur
in the following exons in NF1: exon 7, exon 38, exon 50, and
exon 56. Thomson et al. [9] reported the first new exon
mutation in exon 26 of the NF1 gene (A4435G, Ser1479Gly).
Analysis of exons 24 to 29 showed that a new mutation in
exon 26 affecting RNA splicing resulted in skipped reading
phenomenon of the first 68 amino acids in exon 26, which
caused a reading frameshiftmutation, as analyzed by RT-PCR
technique.Messiaenetal. [6] foundthata mutation(A1466G)
in the region of exon 10 also had a dormant splicing receptor,
which can lead to frameshift mutations.
The effect of mutations on gene transcriptional levels has
been reported in recent years [1, 7]. The rates of occurrence
of other mutations, including large gene-fragment insertions
and large gene-fragment deletions, are less than 5%. Chro-
mosomal translocation and inversion are rare types of muta-
tions. The rate of occurrence of mutations caused by large
gene-fragment deletions, covering the whole NF1 gene and
the neighboring genes, is about 2% to 10%, and it mainly
Table 2 PCR reaction system setup
PCR reaction system Volume (μl)
Phusion® high-fidelity DNA polymerase 0.5
Phusion® HF buffer pack (5×) 10
Deoxynucleotide solution mix (10 mM) 1
DMSO (100%) 1.5
F primer (2.5 μM) 1 l
R primer (2.5 μM) 1
DNA template 1
H2O3 4
Total volume 50
Fig. 6 Exon 19
726 Childs Nerv Syst (2012) 28:721–727leads to a deletion through simple sequence repeats [2, 8].
Studies confirmed that deletions of 112 Mb and 114 Mb are,
presently, the most common types of deletions. Other
researchers also reported one case in which 2-Mb fragments
of the NF1 gene was absent; this fragment was absent
mainly in the paternal chromosome. The patient with deleted
type of mutations may show disease manifestations at a rela-
tively early age and will have malformations and mental
retardation [5].
In this study, we detected point mutation in the exonic
region of the NF1 gene in four type I nerve fibroma patients
and one normal healthy subject in a family by using DNA
direct sequencing and cloning techniques. We found a new
SNP in the NF1 exon, which was located on the third codon
with an unaltered amino acid sequence encoding for synon-
ymous mutated exons, such as exons 7, 38, 50, and 56.
Cloning and sequencing confirmed that the mutation in exon
19 is CAG homozygous, and that in other samples is C/TAG
heterozygous. The presence of the terminal codon led to
degradation of the NF1 mRNA under the NMD mechanism,
which in turn resulted in a unique copy of the NF1 gene
encoding for the normal NF1 protein. We believe this to
probably be the first report on NF1 mutation, and our data
will supplement genetic and clinical databases and further
enrich NF1 pathogenic genetic mutation map. Our study has
provided new data on patients with NF1 and will help
understand the genetic mechanism underlying this condition.
Our data will also provide a basis for future investigations
involving NF1 genetic screening and subsequent diagnosis
and treatment.
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